Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 16, 2014

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Adult Solid NeoplasmChildhood Solid NeoplasmRecurrent Childhood Central Nervous System NeoplasmRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorRecurrent Malignant Solid NeoplasmRefractory Central Nervous System Neoplasm
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Talazoparib

Given PO

DRUG

Temozolomide

Given PO

Trial Locations (22)

10032

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

20010

Children's National Medical Center, Washington D.C.

30322

Children's Healthcare of Atlanta - Egleston, Atlanta

35233

Children's Hospital of Alabama, Birmingham

38105

St. Jude Children's Research Hospital, Memphis

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46202

Riley Hospital for Children, Indianapolis

48109

C S Mott Children's Hospital, Ann Arbor

53226

Children's Hospital of Wisconsin, Milwaukee

55455

University of Minnesota/Masonic Cancer Center, Minneapolis

60611

Lurie Children's Hospital-Chicago, Chicago

63110

Washington University School of Medicine, St Louis

77030

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston

80045

Children's Hospital Colorado, Aurora

90027

Children's Hospital Los Angeles, Los Angeles

92868

Children's Hospital of Orange County, Orange

94143

UCSF Medical Center-Parnassus, San Francisco

94158

UCSF Medical Center-Mission Bay, San Francisco

97239

Oregon Health and Science University, Portland

98105

Seattle Children's Hospital, Seattle

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02116777 - Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies | Biotech Hunter | Biotech Hunter